PSMB10 and leukemia: A significant delay in AML development and a reduction in mortality were observed in the 2nd recipient mice transplanted with AraC- and doxorubicin (ADM)-treated Psmb10−/− MA9 mouse BM leukemia cells, compared to those receiving Psmb10+/+ MA9 cells (32 days vs 19.5 days, p = 0.0014; F ig. 4I).